130 related articles for article (PubMed ID: 16172243)
1. A prospective study of the insulin-like growth factor axis in relation with prostate cancer in the SU.VI.MAX trial.
Meyer F; Galan P; Douville P; Bairati I; Kegle P; Bertrais S; Czernichow S; Hercberg S
Cancer Epidemiol Biomarkers Prev; 2005 Sep; 14(9):2269-72. PubMed ID: 16172243
[TBL] [Abstract][Full Text] [Related]
2. Insulin-like growth factors and prostate cancer: a population-based case-control study in China.
Chokkalingam AP; Pollak M; Fillmore CM; Gao YT; Stanczyk FZ; Deng J; Sesterhenn IA; Mostofi FK; Fears TR; Madigan MP; Ziegler RG; Fraumeni JF; Hsing AW
Cancer Epidemiol Biomarkers Prev; 2001 May; 10(5):421-7. PubMed ID: 11352850
[TBL] [Abstract][Full Text] [Related]
3. Serum insulin-like growth factor I: tumor marker or etiologic factor? A prospective study of prostate cancer among Finnish men.
Woodson K; Tangrea JA; Pollak M; Copeland TD; Taylor PR; Virtamo J; Albanes D
Cancer Res; 2003 Jul; 63(14):3991-4. PubMed ID: 12873996
[TBL] [Abstract][Full Text] [Related]
4. Circulating insulin-like growth factor-I and binding protein-3 and risk of prostate cancer.
Severi G; Morris HA; MacInnis RJ; English DR; Tilley WD; Hopper JL; Boyle P; Giles GG
Cancer Epidemiol Biomarkers Prev; 2006 Jun; 15(6):1137-41. PubMed ID: 16775172
[TBL] [Abstract][Full Text] [Related]
5. Prostate carcinoma incidence in relation to prediagnostic circulating levels of insulin-like growth factor I, insulin-like growth factor binding protein 3, and insulin.
Chen C; Lewis SK; Voigt L; Fitzpatrick A; Plymate SR; Weiss NS
Cancer; 2005 Jan; 103(1):76-84. PubMed ID: 15540247
[TBL] [Abstract][Full Text] [Related]
6. High levels of circulating insulin-like growth factor-I increase prostate cancer risk: a prospective study in a population-based nonscreened cohort.
Stattin P; Rinaldi S; Biessy C; Stenman UH; Hallmans G; Kaaks R
J Clin Oncol; 2004 Aug; 22(15):3104-12. PubMed ID: 15284261
[TBL] [Abstract][Full Text] [Related]
7. Serum insulin-like growth factor (IGF) and IGF-binding protein levels and risk of lung cancer: a case-control study nested in the beta-Carotene and Retinol Efficacy Trial Cohort.
Spitz MR; Barnett MJ; Goodman GE; Thornquist MD; Wu X; Pollak M
Cancer Epidemiol Biomarkers Prev; 2002 Nov; 11(11):1413-8. PubMed ID: 12433720
[TBL] [Abstract][Full Text] [Related]
8. Insulin-like growth factor-I, its binding proteins (IGFBP-1 and IGFBP-3), and growth hormone and breast cancer risk in The Nurses Health Study II.
Schernhammer ES; Holly JM; Hunter DJ; Pollak MN; Hankinson SE
Endocr Relat Cancer; 2006 Jun; 13(2):583-92. PubMed ID: 16728584
[TBL] [Abstract][Full Text] [Related]
9. Insulin-like growth factor II and colorectal cancer risk in women.
Hunt KJ; Toniolo P; Akhmedkhanov A; Lukanova A; Dechaud H; Rinaldi S; Zeleniuch-Jacquotte A; Shore RE; Riboli E; Kaaks R
Cancer Epidemiol Biomarkers Prev; 2002 Sep; 11(9):901-5. PubMed ID: 12223436
[TBL] [Abstract][Full Text] [Related]
10. Serum insulin-like growth factors, insulin-like growth factor binding proteins, and breast cancer risk in postmenopausal women.
Grønbaek H; Flyvbjerg A; Mellemkjaer L; Tjønneland A; Christensen J; Sørensen HT; Overvad K
Cancer Epidemiol Biomarkers Prev; 2004 Nov; 13(11 Pt 1):1759-64. PubMed ID: 15533904
[TBL] [Abstract][Full Text] [Related]
11. Circulating insulin-like growth factor-I and binding protein-3 and the risk of breast cancer.
Baglietto L; English DR; Hopper JL; Morris HA; Tilley WD; Giles GG
Cancer Epidemiol Biomarkers Prev; 2007 Apr; 16(4):763-8. PubMed ID: 17416768
[TBL] [Abstract][Full Text] [Related]
12. Insulin-like growth factor (IGF)-1, IGF-binding protein-3, and pancreatic cancer in male smokers.
Stolzenberg-Solomon RZ; Limburg P; Pollak M; Taylor PR; Virtamo J; Albanes D
Cancer Epidemiol Biomarkers Prev; 2004 Mar; 13(3):438-44. PubMed ID: 15006921
[TBL] [Abstract][Full Text] [Related]
13. Insulin-like growth factor-I and insulin are associated with the presence and advancement of adenomatous polyps.
Schoen RE; Weissfeld JL; Kuller LH; Thaete FL; Evans RW; Hayes RB; Rosen CJ
Gastroenterology; 2005 Aug; 129(2):464-75. PubMed ID: 16083703
[TBL] [Abstract][Full Text] [Related]
14. Insulin resistance, apoptosis, and colorectal adenoma risk.
Keku TO; Lund PK; Galanko J; Simmons JG; Woosley JT; Sandler RS
Cancer Epidemiol Biomarkers Prev; 2005 Sep; 14(9):2076-81. PubMed ID: 16172212
[TBL] [Abstract][Full Text] [Related]
15. Putative role of serum insulin-like growth factor-1 (IGF-1) and IGF binding protein-3 (IGFBP-3) levels in the development of prostate cancer in Arab men.
Kehinde EO; Akanji AO; Mojiminiyi OA; Bashir AA; Daar AS; Varghese R
Prostate Cancer Prostatic Dis; 2005; 8(1):84-90. PubMed ID: 15775992
[TBL] [Abstract][Full Text] [Related]
16. Insulin-like growth factors and risk of benign prostatic hyperplasia.
Chokkalingam AP; Gao YT; Deng J; Stanczyk FZ; Sesterhenn IA; Mostofi FK; Fraumeni JF; Hsing AW
Prostate; 2002 Jul; 52(2):98-105. PubMed ID: 12111701
[TBL] [Abstract][Full Text] [Related]
17. Prostate cancer risk in relation to selected genetic polymorphisms in insulin-like growth factor-I, insulin-like growth factor binding protein-3, and insulin-like growth factor-I receptor.
Chen C; Freeman R; Voigt LF; Fitzpatrick A; Plymate SR; Weiss NS
Cancer Epidemiol Biomarkers Prev; 2006 Dec; 15(12):2461-6. PubMed ID: 17164371
[TBL] [Abstract][Full Text] [Related]
18. Plasma insulin-like growth factor-1 and binding protein-3 and subsequent risk of prostate cancer in the PSA era.
Platz EA; Pollak MN; Leitzmann MF; Stampfer MJ; Willett WC; Giovannucci E
Cancer Causes Control; 2005 Apr; 16(3):255-62. PubMed ID: 15947877
[TBL] [Abstract][Full Text] [Related]
19. Serum levels of insulin-like growth factor-I and -II and insulin-like growth factor binding protein 3 in women with squamous intraepithelial lesions and cervical cancer.
Serrano ML; Romero A; Cendales R; Sánchez-Gómez M; Bravo MM
Biomedica; 2006 Jun; 26(2):258-68. PubMed ID: 16925098
[TBL] [Abstract][Full Text] [Related]
20. Body shape throughout life and correlations with IGFs and GH.
Schernhammer ES; Tworoger SS; Eliassen AH; Missmer SA; Holly JM; Pollak MN; Hankinson SE
Endocr Relat Cancer; 2007 Sep; 14(3):721-32. PubMed ID: 17914102
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]